Prognostic Significance of PD-L۱ and PTEN Expression in Prostatic Cancer
Publish place: Middle East Journal of Cancer، Vol: 13، Issue: 2
Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 50
This Paper With 8 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_MISJ-13-2_005
تاریخ نمایه سازی: 25 آبان 1402
Abstract:
Background: Programmed death- ligand ۱(PD-L۱) acts as an immune checkpoint inhibitor. Phosphatase and tensin homolog (PTEN) is a somatically mutated tumor suppressor gene in numerous types of human cancer. The current study aimed to assess the prognostic value of PD-L۱ and PTEN expression in prostatic cancer patients, as well as their relationship with the clinicopathological features of the disease.Method: A total of ۵۵ needle biopsy specimens were retrospectively diagnosed as prostatic adenocarcinoma. Immunohistochemical staining with PD-L۱ and PTEN were evaluated in all the cases. The patients were followed up for ۵ years in order to detect disease recurrence and survival.Results: PD-L۱ expression in Prostate cancer was positively correlated with high prostatic specific antigen (PSA), higher Gleason score, advanced stage, higher tumor relapse, and worse disease-free and overall survival (P < ۰.۰۰۱). PTEN loss was significantly associated with high PSA, higher Gleason score < ۷, advanced tumor stage, tumor relapse, and worse disease-free and overall survival (P < ۰.۰۰۱). We observed a significant negative correlation between PTEN and PD-L۱.Conclusion: PDL-۱ and PTEN are prognostic markers for prostate cancer, which can differentiate between the patients who are at a high risk of disease progression and may successively provide novel targeted therapies.
Keywords:
Authors
Noha Elaidy
Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt
Eman Abdelbary
Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt
Mohamed Hegazy
Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt
Amira Elwan
Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :